VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates (ADCs), and bispecific antibody-drug conjugates (bsADCs). NAMs are non-animal testing methods that can better predict human responses, aligning with global regulatory shifts toward more ethical and efficient drug development. This matters because traditional animal testing is costly, time-consuming, and often fails to predict human outcomes, contributing to high attrition rates in oncology trials.
The company said its lead BiTAC-TCE and bsADC candidates were also evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer (NSCLC). The panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
This development is significant for several reasons. First, it positions VERAXA at the forefront of a regulatory and ethical shift in drug development. The FDA has been encouraging the adoption of NAMs as part of its modernization efforts, and companies that successfully integrate these methods may benefit from faster review and greater stakeholder goodwill. Second, reducing animal testing addresses growing public and investor concern about animal welfare, which can enhance a company’s environmental, social, and governance (ESG) profile. Third, by cutting the number of mice needed from over 200 to about 10, VERAXA can potentially save substantial costs and shorten timelines, enabling faster iteration and more efficient allocation of resources.
For investors, this update signals that VERAXA is not only advancing its pipeline but also adopting innovative methodologies that could improve success rates in clinical trials. The ability to de-risk candidates earlier using human-relevant models may increase the probability of technical and regulatory success, a key driver of long-term value in biotech. Moreover, the strategy aligns with broader industry trends toward precision medicine and alternatives to animal testing, which are gaining traction among regulators and payers.
To view the full press release, visit https://ibn.fm/9YRJw. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
While the company’s forward-looking statements are subject to risks and uncertainties, the move toward FDA-aligned NAMs represents a strategic step that could differentiate VERAXA in the competitive oncology landscape. If successful, this approach may serve as a model for other biotechs seeking to streamline preclinical development while addressing ethical and regulatory imperatives.
